Syntropic Medical

Advancing mental health care through innovative new solutions.

Syntropic Medical

Syntropic Video Fallback

Advancing mental health care through innovative new solutions

Wave Background in Container

Syntropic offers a non-invasive and non-pharmaceutical treatment for mental health disorders. Through light stimulation, neural remodeling is activated by instructing the immune cells of the brain to support in healing and recovery.

Syntropic is a clinical stage medical device company developing new technologies that enhance the brain’s neuroplasticity, allowing for the treatment of psychiatric disorders and the improvement of cognition.

 

Syntropic's mission is to advance mental health care through the development of innovative technologies that target underlying causes of brain disorders.

Psychiatric disorders are a severe burden on society

Psychiatric disorders have become a severe burden on society. In Europe alone, an estimated 90M people are living with depression. For those people, the standard treatment options remain to be antidepressants which have now been in use for over 50 years. These options are no longer good enough, where over 50% of people will relapse and over 30% of patients will receive no benefit at all. However, new therapies are beginning to offer hope in the treatment of psychiatric disorders by focusing their efforts on modifying brain circuits, enabling the brain to form new connections and remodel itself.

Syntropic, providing a non-invasive alternative to drug therapy

While researching alternative therapies in this space, Syntropic's founders, in Venturino et al., 2021, made a breakthrough discovery whereby the immune cells of the brain could be instructed to alter structures in the brain associated with mental health conditions, all while using a non‑pharmaceutical and non‑invasive approach. This demonstration showed that Syntropic's light-based therapy reduces symptoms of depression and promotes cognitive function. This was achieved without any side effects, free of pharmaceuticals, and at low cost. Clinical development is now underway to deliver this technology to those who need it most.

Advancing mental health care for the unmet needs of patients

For patients who fail to receive the clinical benefit and/or struggle with the side‑effects of existing therapies, Syntropic offers a new and novel solution that has the potential to provide long‑lasting relief from psychiatric illness. With a focus on accessibility, affordability, and patient usability, the solution offers significant benefits to both patients and healthcare systems. Syntropic aims to transform the landscape of mental health care through the advancement of health technology for the unmet needs of patients.

Meet our team​

Interested in joining our team? View our available jobs. Or become part of our journey to the new frontier of psychiatric care by reaching out to info@syntropicmedical.com and following us on social media.

Mark Caffrey

Co-Founder and CEO

Alessandro Venturino

Co-Founder and Head of Research

Jack O'Keeffe

Co-Founder and CTO

Sandra Siegert

Co-Founder and Scientific Advisor

Maria Teresa Ferretti

Clinical Development Lead

Friederike Leesch

Biomedical Researcher

Francesca Giovanetti

Founders Associate

Federica Montrone

Medical Device Engineer

Articles

Microglia Enable Mature Perineuronal Nets Disassembly upon Anesthetic Ketamine Exposure or 60 Hz Light Entrainment in the Healthy Brain

Syntropic Medical secures early-stage funding from xista science ventures and aws

Repeated Ketamine Anesthesia Restarts Plasticity in the Brain

Vienna-based Syntropic secures seven-figure funding to develop new treatment for Major Depressive Disorder

Supporters